1-2 of 2
Michela Anghilieri
Close
Sort by
Journal Articles

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Clinical Trials & Observations
Margherita Maffioli, Barbara Mora, Somedeb Ball, Alessandra Iurlo, Elena Maria Elli, Maria Chiara Finazzi, Nicola Polverelli, Elisa Rumi, Marianna Caramella, Maria Cristina Carraro, Mariella D’Adda, Alfredo Molteni, Cinzia Sissa, Francesca Lunghi, Alessandro Vismara, Marta Ubezio, Anna Guidetti, Sabrina Caberlon, Michela Anghilieri, Rami Komrokji, Daniele Cattaneo, Matteo Giovanni Della Porta, Toni Giorgino, Lorenza Bertù, Marco Brociner, Andrew Kuykendall, Francesco Passamonti
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1855–1864.
https://doi.org/10.1182/bloodadvances.2021006889
Published: 2022
Includes: Supplemental data
Journal Articles

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Clinical Trials & Observations
Margherita Maffioli, Toni Giorgino, Barbara Mora, Alessandra Iurlo, Elena Elli, Maria Chiara Finazzi, Marianna Caramella, Elisa Rumi, Maria Cristina Carraro, Nicola Polverelli, Mariella D’Adda, Simona Malato, Marianna Rossi, Alfredo Molteni, Alessandro Vismara, Cinzia Sissa, Francesco Spina, Michela Anghilieri, Daniele Cattaneo, Rossella Renso, Marta Bellini, Maria Luisa Pioltelli, Chiara Cavalloni, Daniela Barraco, Raffaella Accetta, Lorenza Bertù, Matteo Giovanni Della Porta, Francesco Passamonti
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3196–3200.
https://doi.org/10.1182/bloodadvances.2019000646
Published: 2019
Includes: Supplemental data